Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urinary Analysis in Early Pregnancy Predicts Likelihood of Preterm Birth

By LabMedica International staff writers
Posted on 24 Jul 2014
Analysis of metabolites in the urine during the early stages of pregnancy was found to be an effective approach for predicting the likelihood of a preterm birth.

Preterm birth (PB) and fetal growth restriction (FGR) convey high risk of infant mortality and morbidity, as well as increasing the chance of developing chronic disease in later life. More...
Biomarkers identified early in pregnancy could predict poor birth outcomes and aid in their prevention and management.

Investigators at Imperial College London (United Kingdom) and the University of Crete (Greece) used proton nuclear magnetic resonance spectroscopy to analyze metabolites in urine samples obtained at the first ultrasound appointment from 438 pregnant women in the Rhea cohort. The Rhea cohort is a large population case-control mother-child study that started in Crete in 2007.

Results revealed that elevated urinary levels of lysine were associated with spontaneous premature birth. Decreased levels of acetate, formate, tyrosine, and trimethylamine were associated with poor fetal development. Women with decreased levels of these urine metabolites also showed signs of an increased risk of diabetes, such as higher blood insulin. Increased levels of an N-acetylated glycoprotein were significantly associated with induced preterm birth (IPB) in overweight and obese women only.

Senior author Dr. Hector Keun, senior lecturer in biological chemistry at Imperial College London, said, "While we know that metabolism in the mother changes substantially during pregnancy to help supply the growing fetus with nutrients, we were surprised to see so early in pregnancy a link between metabolites that we could easily detect in a urine sample and low birth weight. Our findings imply that it could be possible to improve the identification of women at higher risk of delivering smaller babies or premature delivery using noninvasive metabolic profiling technology early in pregnancy. Future investigation of the factors that produce the molecules associated with these pregnancy outcomes should improve our understanding of the genetic and environmental factors that influence restricted fetal growth and thus help us to reduce the likelihood of these events. We will also go on to test if exposure to these metabolites during pregnancy has a lasting impact on child development after birth."

The urine metabolites study was published in the July 11, 2014, online edition of the journal BMC Medicine.


Related Links:

Imperial College London

University of Crete




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.